

Oliver Caswell
request-875904-d41b634b@whatdotheyknow.com

Ref: 7207 2022

08 August 2022

Dear Requester

Request under Freedom of Information Act 2000

Thank you once again for your request under the Freedom of Information Act. For ease of reference I am attaching your original questions:

1) In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?

2) Of these five, how many of each received the following products:

- Adalimumab (Humira)
- Adalimumab Biosimilar
- Etanercept (Enbrel)
- Etanercept Biosimilar
- Infliximab (Remicade)
- Infliximab biosimilar
- Golimumab (Simponi)
- Tofacitinib (Xeljanz)
- Ustekinumab (Stelara)
- Vedolizumab (Entyvio)
- Filgotinib (Jyseleca)

- Abatacept (Orencia)
- Baricitinib (Olumiant)
- Certolizumab Pegol (Cimzia)
- Rituximab (MabThera)
- Rituximab Biosimilar
- Tocilizumab (RoActemra)
- Sarilumab (Kevzara)
- Apremilast (Otezla)
- Secukinumab (Cosentyx)
- Isekizumab (Taltz)
- Guselkumab (Tremfya)
- Brodalumab (Kyntheum)
- Risankizumab (Skyrizi)
- Tildrakizumab (Ilumetri)
- Upadacitinib (Rinvoq)
- Bimekizumab (Bimzelx)

3) Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).

4) Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

- AxSPA
- PsA
- PsO

Please find attached the response to your request.



FOI 7207 2022
Response.pdf

Please note that the information provided is the property of the Royal Surrey NHS Foundation Trust and is subject to Intellectual Property Database rights. Any commercial application or use of this information may be subject to the provisions of the Re-use of Public Sector Information Regulations 2015. This means that if you wish to re-use the information provided for commercial purposes for any reason you must ask us for permission to do so.

This letter confirms the completion of this request. A log of this request will be held on a database held by the Trust.

I hope the information provided meets your needs. If you are dissatisfied with the Trust's response, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of the response to your original request and should be sent to the Trust Company Secretary, at the address at the top of this letter.

If you are not content with the outcome of the internal review, you have the right under Section 50 of the Freedom of Information Act 2000 to apply directly to the Information Commissioner for a decision on whether your application has been dealt with in accordance with the Act. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Yours sincerely

Freedom of Information
Royal Surrey NHS Foundation Trust